195 related articles for article (PubMed ID: 29675397)
1. Personalizing Breast Cancer Irradiation Using Biology: From Bench to the Accelerator.
Azria D; Brengues M; Gourgou S; Bourgier C
Front Oncol; 2018; 8():83. PubMed ID: 29675397
[TBL] [Abstract][Full Text] [Related]
2. HYPofractionated Adjuvant RadioTherapy in 1 versus 2 weeks in high-risk patients with breast cancer (HYPART): a non-inferiority, open-label, phase III randomised trial.
Yadav BS; Dahiya D; Kannan P; Goyal S; Laroiya I; Irrinki S; Singh NR; Sharma R
Trials; 2024 Jan; 25(1):21. PubMed ID: 38167339
[TBL] [Abstract][Full Text] [Related]
3. How could breast cancer molecular features contribute to locoregional treatment decision making?
Tsoutsou PG; Vozenin MC; Durham AD; Bourhis J
Crit Rev Oncol Hematol; 2017 Feb; 110():43-48. PubMed ID: 28109404
[TBL] [Abstract][Full Text] [Related]
4. Locoregional relapse is a strong prognostic indicator of distant metastatic progression in breast cancer patients after negative sentinel lymph node biopsy.
Falco M; Masojć B; Kram A
Breast J; 2020 Dec; ():. PubMed ID: 33289332
[TBL] [Abstract][Full Text] [Related]
5. [Influence of locoregional irradiation on local control and survival in breast cancer].
Cutuli B
Cancer Radiother; 1998; 2(5):446-59. PubMed ID: 9868387
[TBL] [Abstract][Full Text] [Related]
6. Precision Medicine and the Role of Biomarkers of Radiotherapy Response in Breast Cancer.
Meehan J; Gray M; Martínez-Pérez C; Kay C; Pang LY; Fraser JA; Poole AV; Kunkler IH; Langdon SP; Argyle D; Turnbull AK
Front Oncol; 2020; 10():628. PubMed ID: 32391281
[TBL] [Abstract][Full Text] [Related]
7. [Evidence-based radiotherapy in the treatment of early-stage invasive breast cancer: traditional clinical features and biomarkers].
Fodor J
Magy Onkol; 2009 Mar; 53(1):7-14. PubMed ID: 19318321
[TBL] [Abstract][Full Text] [Related]
8. [Breast cancer: value of postoperative locoregional irradiation following mastectomy].
Cutuli B
Presse Med; 2000 Mar; 29(8):439-46. PubMed ID: 10738513
[TBL] [Abstract][Full Text] [Related]
9. Recent Advances in Optimizing Radiation Therapy Decisions in Early Invasive Breast Cancer.
Riaz N; Jeen T; Whelan TJ; Nielsen TO
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831598
[TBL] [Abstract][Full Text] [Related]
10. T1-T2 breast cancer with four or more positive axillary lymph nodes: adjuvant locoregional radiotherapy with high-dose or standard-dose chemotherapy. Results of an observational study.
Perrucci E; Aristei C; De Angelis V; Anselmo P; Mascioni F; Gori S; Frattegiani A; Latini P
Tumori; 2004; 90(4):379-86. PubMed ID: 15510979
[TBL] [Abstract][Full Text] [Related]
11. [Cancer of the breast: results and toxicity of locoregional irradiation after mastectomy].
Cutuli B
Cancer Radiother; 2000 Nov; 4 Suppl 1():167s-179s. PubMed ID: 11194957
[TBL] [Abstract][Full Text] [Related]
12. Impact of postmastectomy radiotherapy on the outcomes of breast cancer patients with T1-2 N1 disease : An individual patient data analysis of three clinical trials.
Abdel-Rahman O
Strahlenther Onkol; 2019 Apr; 195(4):297-305. PubMed ID: 30069737
[TBL] [Abstract][Full Text] [Related]
13. Radiotherapy after skin-sparing mastectomy with immediate breast reconstruction in intermediate-risk breast cancer : Indication and technical considerations.
Hehr T; Baumann R; Budach W; Duma MN; Dunst J; Feyer P; Fietkau R; Haase W; Harms W; Krug D; Piroth MD; Sedlmayer F; Souchon R; Wenz F; Sauer R;
Strahlenther Onkol; 2019 Nov; 195(11):949-963. PubMed ID: 31451835
[TBL] [Abstract][Full Text] [Related]
14. A Precise Approach for Radiotherapy of Breast Cancer.
Sigurdson S; Thibodeau S; Korzeniowski M; Moraes FY
Cancer Treat Res; 2023; 188():175-198. PubMed ID: 38175346
[TBL] [Abstract][Full Text] [Related]
15. From technological advances to biological understanding: The main steps toward high-precision RT in breast cancer.
Leonardi MC; Ricotti R; Dicuonzo S; Cattani F; Morra A; Dell'Acqua V; Orecchia R; Jereczek-Fossa BA
Breast; 2016 Oct; 29():213-22. PubMed ID: 27542556
[TBL] [Abstract][Full Text] [Related]
16. Management of the Axilla in the Era of Breast Cancer Heterogeneity.
de Meric de Bellefon M; Lemanski C; Ducteil A; Fenoglietto P; Azria D; Bourgier C
Front Oncol; 2018; 8():84. PubMed ID: 29670853
[TBL] [Abstract][Full Text] [Related]
17. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
[TBL] [Abstract][Full Text] [Related]
18. Late toxicities and outcomes of adjuvant radiotherapy combined with concurrent bevacizumab in patients with triple-negative non-metastatic breast cancer.
Pernin V; Belin L; Cottu P; Bontemps P; Lemanski C; De La Lande B; Baumann P; Missohou F; Levy C; Peignaux K; Reynaud-Bougnoux A; Denis F; Gobillion A; Bollet M; Vago NA; Dendale R; Campana F; Fourquet A; Kirova YM
Br J Radiol; 2015 Apr; 88(1048):20140800. PubMed ID: 25645108
[TBL] [Abstract][Full Text] [Related]
19. Late side-effects after curative intent radiotherapy: Identification of hypersensitive patients for personalized strategy.
Bourgier C; Lacombe J; Solassol J; Mange A; Pèlegrin A; Ozsahin M; Azria D
Crit Rev Oncol Hematol; 2015 Mar; 93(3):312-9. PubMed ID: 25497158
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
